Parkinson’s Diagnostics Industry Tracks Blood Sensor Data

KAUST and Oxford Researchers Report Blood Sensor Detecting Three Alpha-Synuclein Forms in 40 Minutes

OXFORD, United Kingdom — October 15, 2026 — Researchers at King Abdullah University of Science and Technology (KAUST) and the University of Oxford have developed a blood-based electronic sensor that detects three forms of alpha-synuclein associated with Parkinson’s disease. The findings, published in Science Advances, are relevant to the Parkinson’s disease diagnostics market, where less invasive tools for earlier diagnosis are a stated area of development.

The sensor uses a transistor to amplify biological signals, allowing all three protein forms to be measured at the same time within 40 minutes. The method first isolates small packages released by nerve cells into the bloodstream and then analyses their protein contents.

Detection in blood is difficult because more than 95% of circulating alpha-synuclein comes from red blood cells, which creates substantial background noise. Isolating the nerve-cell packages is the approach the researchers used to address this.

In a blinded evaluation of 59 participants from the Oxford Discovery cohort, the platform reached 90.9% accuracy in distinguishing disease-associated profiles from healthy controls. The cohort included people with Parkinson’s disease, healthy controls and people with isolated REM sleep behaviour disorder, a condition associated with a higher risk of developing Parkinson’s.

The researchers said the platform is not yet a standalone clinical blood test. The study was a retrospective evaluation in an initial cohort. Larger prospective, multicentre studies are needed to establish its predictive value before routine use.

Key Highlights:

• The transistor-based sensor measures three alpha-synuclein forms simultaneously in 40 minutes.

• Accuracy was 90.9% in a blinded evaluation of 59 participants from the Oxford Discovery cohort.

• The three forms showed distinct patterns across the groups, suggesting that measuring them together may add diagnostic information compared with a single marker.

• The study was retrospective, and larger prospective, multicentre validation is required before clinical adoption.

Analyst Insight:

According to analysts at Next Move Strategy Consulting, the global Parkinson’s disease diagnostics market was valued at USD 4.53 billion in 2025 and is projected to reach USD 11.00 billion by 2035, a compound annual growth rate of 9.28% from 2026 to 2035.

NMSC analysts note that biomarker assays are the fastest-growing diagnostic modality, with a projected CAGR of 13.86% from 2026 to 2035. They expect the segment’s share of revenue to rise from 22.5% in 2025 to 33.6% by 2035. They add that multicentre validation and payer coverage will determine how quickly less invasive blood-based formats move into routine neurology pathways.

Industry Outlook:

The research adds to work on blood-based alpha-synuclein detection as an alternative to more invasive sample collection. Its progress will depend on larger prospective studies, as the researchers stated. Regulatory review, assay standardisation and reimbursement will also shape whether such sensors enter clinical use.

Source: Pharmafile

For More Information: Download FREE Sample on Parkinson's Disease Diagnostics Market

Prepared By: Sanyukta Deb